ECE2021 Eposter Presentations Thyroid (43 abstracts)
Endocrinology, Pierre Marie Curie Center of Medecine, Algiers, Algeria
Introduction
Graves disease is an autoimmune thyroid disease manifested by hyperthyroidism, homogeneous goiter and sometimes ophthalmopathy. The frequency of the disease is less than 1% with a female predominance of 510/1 male. Its treatment is difficult because of the evolving vagaries of this disease. We report the results of surgery for Graves disease through a retrospective study.
Material and methods
100 files of patients operated on for Graves disease (MB) either as first-line after preparation for medical treatment (average duration of less than 6 months) in 9 or after failure of medical treatment in 91%.
Results
Average age: between (2060 years)
Female predominance
Reason for consultation: goiter + signs of hyperthyroidism): 79%
Basedowian ophthalmopathy 69%.
Palpation of the neck: goiter type 2: 74 (firm, elastic, vascular in 70%)
The thyroid hormone balance: TSHus slowed down in all cases (avg: 0.12 U/ml) associated with an increase in peripheral hormones FT3 and/or FT4.
The autoimmunity assessment
Anti TPO Ab: 13% positive, Anti TSHus receptor TSI 20% positive, TG Ab 3% positive
Surgery results
65% of patients (P) underwent a total thyroidectomy.
35% (P): subtotal thyroidectomy
Histology
82% of patients: Typical basal disease
17% (P) Graves disease associated with cell variants
• Oncocytic metaplasia
• Functional hyperplasia
1% (P) papillary microcarcinoma + MB.
Conclusion
The management of Graves disease requires a precise diagnosis as well as an appropriate treatment. Follow-up depends on the speed of the response and the occurrence of recurrence. The medical treatment for Graves disease takes a long time. It imposes physical and economic constraints with a high rate of relapses. If remission does not occur radical treatment is indicated by radioiodine or surgery.